肺部多发磨玻璃结节(ground-glass nodule,GGN)是早期肺癌的主要影像学特征,其发病率呈现逐年上升趋势.即使采用手术切除主要病灶,仍有21%的患者在术后2年出现第二原发肺癌,并且由于肺功能受损而难以再次手术.因此,如何实现微无创局部治愈早期肺癌,提升肺癌二级预防的效果,是肺癌防治领域的重大挑战和研究前沿.2022年,《肺部多发磨玻璃结节中西医结合防治一体化专家共识》首次提出中医药修复线粒体联合消融(ablation and mitochondrial therapy with Traditional Chinese Medicine,AMTC)的创新诊疗方案,为肺GGN的中西医结合诊疗提供了重要的理论和实践依据.2022年以来,中医药防治肺癌取得重大突破,AMTC中西医结合创新诊疗技术日臻成熟,中国抗癌协会肺癌整合防筛专业委员会(The Lung Cancer Integrated Prevention and Screening Special Committee of the Chinese Anti-Cancer Association)和上海市医师协会整合医学分会(Shanghai Medical Doctor Association Integrative Medicine Branch)决定对本共识进行修订.本共识首次发布AMTC创新诊疗规范,系统阐述中西医协同修复受损线粒体逆转肿瘤代谢重编程和炎癌转变的新理论,"西医精准消融+中医药系统修复线粒体"的AMTC临床新技术以及"不开刀"治疗早期肺癌同时预防合并结节癌变的新策略,能有效实现肺癌的二级预防,显著降低肺癌发病率.共识的发布将促进中西医结合诊疗的高质量发展,提升肺癌的防治水平,面向人民健康重大需求,切实响应健康中国战略.
Expert Consensus on the Innovative Diagnosis and Treatment Practice of Integrated Traditional Chinese and Western Medicine(2023 Edition)
Multiple pulmonary ground-glass nodules(GGNs)constitute the primary radiological hallmark of early-stage lung cancer,and their prevalence has exhibited a noteworthy upward trajectory in recent years.Even following surgical excision of the primary lesion,21%of the patients manifest secondary primary lung cancers within two years postoperatively.This,compounded by compromised lung function,engenders substantial challenges in facilitating subsequent surgical interventions.Consequently,the vanguard of research within the domain of lung cancer prevention and treatment revolves around realizing minimally invasive local curative modalities for early-stage lung cancer and enhancing secondary cancer prevention.In 2022,the"Expert Consensus on Integrated Traditional Chinese and Western Medicine Approaches to the Prevention and Treatment of Multiple Pulmonary Ground-Glass Nodules"introduced a pioneering diagnostic and therapeutic scheme denoted as Ablation and Mitochondrial Therapy with Traditional Chinese Medicine(AMTC).This seminal contribution furnished a crucial theoretical and practical underpinning for the integrated diagnostic and therapeutic approaches involving both traditional Chinese and Western medicine in the management of pulmonary GGN.Over the preceding two years,noteworthy strides have been accomplished in the application of traditional Chinese medicine to the prevention and treatment of lung cancer.The AMTC integrated diagnostic and therapeutic technology has matured significantly.In light of these developments,The Lung Cancer Integrated Prevention and Screening Special Committee of the Chinese Anti-Cancer Association and the Shanghai Medical Association Integrative Medicine Branch have undertaken a revision of the preceding consensus.This updated consensus introduces standards for the innovative AMTC diagnostic and therapeutic approach,systematically elucidates the novel theory concerning the collaborative restoration of damaged mitochondria through the synergy of traditional Chinese and Western medicine,as well as the clinical innovation referred to as"precision ablation in Western medicine+systematic mitochondrial restoration in traditional Chinese medicine."Furthermore,it outlines a fresh strategy for non-surgical management of early-stage lung cancer while concurrently mitigating the potential progression of nodular malignancies.This strategy effectively materializes secondary cancer prevention and leads to a substantial reduction in the incidence of lung cancer.The release of this consensus is poised to foster the high-quality evolution of integrated traditional Chinese and Western medicine in diagnosis and treatment,elevate the standards of lung cancer prevention and treatment,and provide a robust response to the"Healthy China"initiative,which addresses the pressing healthcare demands of the populace.
Pulmonary multiple ground-glass nodulesMitochondrial restorationIntegrated traditional Chinese and Western medicinePrevention and treatment of early lung cancerExpert consensus
NETL
NSTL
万方数据
